COST-EFFECTIVENESS ANALYSIS OF MIRABEGRON VERSUS TOLTERODINE EXTENDED RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UNITED STATES
Author(s)
Xie J1, Zhou ZY2, Bui CN3, Yan Y1, De G1, Runken MC4, Wu EQ21Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Astellas Pharma US, Inc., Northbrook, IL, USA, 4Astellas Pharma US, Inc., Glenview, IL, USA
OBJECTIVES: To assess the cost-effectiveness associated with mirabegron versus tolterodine extended release (ER) for treating overactive bladder (OAB) from a third party payer perspective in the US. METHODS: A Markov model was developed to follow a cohort of OAB patients treated with mirabegron versus tolterodine ER for a one-year period. Three health states were defined - normal: number of incontinence (I)=0 and number of micturitions (M)<8; mild-to-moderate: 0
Conference/Value in Health Info
2012-11, ISPOR Europe 2012, Berlin, Germany
Value in Health, Vol. 15, No. 7 (November 2012)
Code
PUK14
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Urinary/Kidney Disorders